LCTX

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological and ophthalmic conditions. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

Wall Street analysts forecast LCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LCTX is 5.00 USD with a low forecast of 3.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Lineage Cell Therapeutics Inc revenue for the last quarter amounts to 3.68M USD, decreased -2.59 % YoY.

Lineage Cell Therapeutics Inc. EPS for the last quarter amounts to -0.13 USD, increased 550.00 % YoY.

Lineage Cell Therapeutics Inc (LCTX) has 70 emplpoyees as of December 16 2025.

Today LCTX has the market capitalization of 392.71M USD.